National Institute on Alcohol Abuse and Alcoholism; Notice of Closed Meetings, 39443 [2017-17428]
Download as PDF
<![CDATA[
Federal Register / Vol. 82, No. 159 / Friday, August 18, 2017 / Notices
(Catalogue of Federal Domestic Assistance
Program No. 93.242, Mental Health Research
Grants, National Institutes of Health, HHS)
Dated: August 14, 2017.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–17430 Filed 8–17–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
[FR Doc. 2017–17428 Filed 8–17–17; 8:45 am]
mstockstill on DSK30JT082PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Alcohol Abuse and Alcoholism Initial
Review Group Epidemiology, Prevention and
Behavior Research Review Subcommittee.
Date: October 23, 2017.
Time: 8:30 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute on Alcohol Abuse and
Alcoholism, Terrace Level Conference
Rooms, 5635 Fishers Lane, Rockville, MD
20852.
Contact Person: Anna Ghambaryan, M.D.,
Ph.D., Scientific Review Officer, Extramural
Project Review Branch, Office of Extramural
Activities, National Institute on Alcohol
Abuse and Alcoholism, National Institutes of
Health, 5635 Fishers Lane, Room 2019,
Rockville, MD 20852, 301–443–4032,
anna.ghambaryan@nih.gov.
Name of Committee: National Institute on
Alcohol Abuse and Alcoholism Initial
Review Group Clinical, Treatment and
Health Services Research Review
Subcommittee.
Date: November 1, 2017.
Time: 8:30 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute on Alcohol Abuse and
Alcoholism, Terrace Level Conference Room
508, 5635 Fishers Lane, Rockville, MD 20852
Contact Person: Ranga V. Srinivas, Ph.D.
Chief Extramural Project Review, Branch
17:47 Aug 17, 2017
Jkt 241001
(Catalogue of Federal Domestic Assistance
Program Nos. 93.271, Alcohol Research
Career Development Awards for Scientists
and Clinicians; 93.272, Alcohol National
Research Service Awards for Research
Training; 93.273, Alcohol Research Programs;
93.891, Alcohol Research Center Grants;
93.701, ARRA Related Biomedical Research
and Research Support Awards., National
Institutes of Health, HHS)
Dated: August 14, 2017.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
National Institute on Alcohol Abuse
and Alcoholism; Notice of Closed
Meetings
VerDate Sep<11>2014
National Institute on Alcohol Abuse and
Alcoholism, National Institutes of Health,
5365 Fishers Lane, Room 2085, Rockville,
MD 20852, (301) 451–2067 srinivar@
mail.nih.gov.
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The invention listed below is
owned by an agency of the U.S.
Government and is available for
licensing to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT:
Peter Soukas, J.D., (301) 594–8730;
peter.soukas@nih.gov. Licensing
information and copies of the patent
applications listed below may be
obtained by communicating with the
indicated licensing contact at the
Technology Transfer and Intellectual
Property Office, National Institute of
Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD, 20852; tel.
(301) 496–2644. A signed Confidential
Disclosure Agreement will be required
to receive copies of unpublished patent
applications.
SUPPLEMENTARY INFORMATION:
Technology description follows.
SUMMARY:
Development of a Transferrable
Norwalk Virus Epitope and Detector
Monoclonal Antibody
Description of Technology
Noroviruses are now recognized as
the major cause of non-bacterial
PO 00000
Frm 00040
Fmt 4703
Sfmt 4703
39443
gastroenteritis in all age groups, and
efforts are underway to develop an
effective vaccine. The lack of a robust
cell culture system for human
noroviruses has complicated vaccine
development. Hence, norovirus virus
like particles (VLPs) have played an
important role in the understanding of
virus structure, immune response,
antigenic diversity, and vaccine design.
The development of monoclonal
antibodies (MAbs) against norovirus
VLPs has allowed the identification and
characterization of key antigenic sites of
the virus capsid and facilitated the
development of diagnostic assays.
During characterization of a panel of
MAbs raised against Norwalk virus
(NV), a prototype norovirus strain, the
inventors identified a monoclonal
antibody (MAbNV10) that proved useful
in the identification of NV in tissue and
in the characterization of an insertion
site in the feline calicivirus (FCV)
genome. The inventors mapped the
precise binding site of the MAb by
peptide screening and discovered that
the epitope could be expressed when
fused to other proteins. The sequence of
this peptide (epitope) along with the
detector antibody could be used as a
new way to tag proteins for functional
studies. The small size of the linear
epitope, along with the strong avidity of
the detector monoclonal antibody makes
this system especially useful for many
techniques, including
immunofluorescence, Western blot,
immunoprecipitation (including
‘‘pulldown’’ assays), and
immunohistochemistry. The inventors’
epitope system may be comparable to
that of the HA tag of influenza virus that
is widely used in molecular biology.
This technology is further described
in Parra et al., ‘‘Mapping and modeling
of a strain-specific epitope in the
Norwalk virus capsid inner shell,’’
Virology. 2016 May;492:232–41. doi:
10.1016/j.virol.2016.02.019. Epub 2016
Mar 21.
Materials available for licensing
comprise: (1) Hybridoma cell line NV10,
(2) Plasmid expressing NV10 epitope as
positive control, and (3) Plasmid
expressing the NV10 scFV.
This technology is available for
licensing for commercial development
in accordance with 35 U.S.C. 209 and 37
CFR part 404, as well as for further
development and evaluation under a
research collaboration.
Potential Commercial Applications
• Diagnostics
• Vaccines
Competitive Advantages
• Cross-reactive norovirus antibody
E:\FR\FM\18AUN1.SGM
18AUN1
]]>Agencies
[Federal Register Volume 82, Number 159 (Friday, August 18, 2017)]
[Notices]
[Page 39443]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-17428]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Alcohol Abuse and Alcoholism; Notice of
Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute on Alcohol Abuse and
Alcoholism Initial Review Group Epidemiology, Prevention and
Behavior Research Review Subcommittee.
Date: October 23, 2017.
Time: 8:30 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, National Institute on
Alcohol Abuse and Alcoholism, Terrace Level Conference Rooms, 5635
Fishers Lane, Rockville, MD 20852.
Contact Person: Anna Ghambaryan, M.D., Ph.D., Scientific Review
Officer, Extramural Project Review Branch, Office of Extramural
Activities, National Institute on Alcohol Abuse and Alcoholism,
National Institutes of Health, 5635 Fishers Lane, Room 2019,
Rockville, MD 20852, 301-443-4032, anna.ghambaryan@nih.gov.
Name of Committee: National Institute on Alcohol Abuse and
Alcoholism Initial Review Group Clinical, Treatment and Health
Services Research Review Subcommittee.
Date: November 1, 2017.
Time: 8:30 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, National Institute on
Alcohol Abuse and Alcoholism, Terrace Level Conference Room 508,
5635 Fishers Lane, Rockville, MD 20852
Contact Person: Ranga V. Srinivas, Ph.D. Chief Extramural
Project Review, Branch National Institute on Alcohol Abuse and
Alcoholism, National Institutes of Health, 5365 Fishers Lane, Room
2085, Rockville, MD 20852, (301) 451-2067 srinivar@mail.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.271,
Alcohol Research Career Development Awards for Scientists and
Clinicians; 93.272, Alcohol National Research Service Awards for
Research Training; 93.273, Alcohol Research Programs; 93.891,
Alcohol Research Center Grants; 93.701, ARRA Related Biomedical
Research and Research Support Awards., National Institutes of
Health, HHS)
Dated: August 14, 2017.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2017-17428 Filed 8-17-17; 8:45 am]
BILLING CODE 4140-01-P
